Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder involving the progressive degeneration of motor neurons in the brain and spinal cord. Mitochondrial dysfunction plays a key role in ALS disease progression and has been observed in several ALS cellular and animal models. Here, we show that fibroblasts isolated from ALS cases with a Cu/Zn superoxide dismutase (SOD1) I113T mutation recapitulate these mitochondrial defects. Using a novel technique, which measures mitochondrial respiration and glycolytic flux simultaneously in living cells, we have shown that SOD1 mutation causes a reduction in mitochondrial respiration and an increase in glycolytic flux. This causes a reduction in adenosine triphosphate produced by oxidative phosphorylation and an increase in adenosine triphosphate produced by glycolysis. Switching the energy source from glucose to galactose caused uncoupling of mitochondria with increased proton leak in SOD1(I113T) fibroblasts. Assessment of the contribution of fatty acid oxidation to total respiration, suggested that fatty acid oxidation is reduced in SOD1 ALS fibroblasts, an effect which can be mimicked by starving the control cells of glucose. These results highlight the importance of understanding the interplay between the major metabolic pathways, which has the potential to lead to strategies to correct the metabolic dysregulation observed in ALS cases.
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Scott P
SP
Allen
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Sandeep
S
Rajan
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Lynn
L
Duffy
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Heather
H
Mortiboys
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Adrian
A
Higginbottom
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Andrew J
AJ
Grierson
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK. Electronic address: pamela.shaw@sheffield.ac.uk.
Pamela J
PJ
Shaw
D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics* / Q000378:metabolism*; D002478:Cells, Cultured; D004734:Energy Metabolism / Q000235:genetics*; D005347:Fibroblasts / Q000201:enzymology / Q000378:metabolism* / Q000648:ultrastructure; D006019:Glycolysis / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D008928:Mitochondria / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D010085:Oxidative Phosphorylation; D012867:Skin / Q000166:cytology; D013482:Superoxide Dismutase / Q000235:genetics* / Q000502:physiology*; D000072105:Superoxide Dismutase-1
C000606290:SOD1 protein, human; D000255:Adenosine Triphosphate; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1
ALS; Metabolism; Mitochondria; SOD1